Congress and Medical Meeting Promotional Booth Compliance
Every decision a pharma or medtech company makes at a medical congress, what to display on a panel, what to hand a clinician, what dinner to fund, sits inside an interlocking set of federal statutes, agency guidance, and industry codes ⟦c1⟧⟦c3⟧. Medical conferences have returned to full scale: ASCO 2025 alone drew 44,900 registrations and 7,400 exhibitors, and booths across major meetings like ASCO, ESC, ESMO, and ASH keep getting more immersive and interactive ⟦c2⟧. That growth in scale does not loosen the regulatory grip on the exhibit hall. It tightens it, because more square footage, more digital touchpoints, and more giveaways simply means more surface area for a claim, a gift, or a data table to violate a rule someone on the design team never read.
The most persistent misunderstanding among marketing teams is treating the booth as a creative asset governed mainly by brand guidelines and square-footage budgets ⟦c3⟧. In practice, it is a regulatory artifact. None of that changes because the booth sits inside a convention center instead of a physician's office. What follows moves through that framework in the order a company actually encounters it: the U.S. regulatory baseline, the industry codes layered on top of it, the financial transparency rules that record what happens at the booth, the separate European overlay for international congresses, and finally, what all of it means for how a booth actually gets planned ⟦c4⟧.
The first design decision: medical affairs booth vs. commercial booth
Before a single panel gets designed, a company has to decide whether the space is an HCP-only exhibition area, where promotional materials are permitted, or a publicly accessible area, where no direct or indirect promotion is allowed, since some congresses operate two such distinct areas and use differently coded lanyards or badges to restrict non-HCPs from promotional zones ⟦c36⟧. A medical booth exists for credibility, scientific exchange, and education. It has to present complex data accurately, create room for real peer-to-peer dialogue between the company's scientific staff and attending clinicians, and do all of that while staying inside regulatory lines, without turning into a lifeless data dump ⟦c5⟧.
A commercial booth, by contrast, centers on brand visibility and promotional messaging. That does not mean it operates with more latitude. Every claim it makes is still bound by the same FDA promotional standards that govern a medical booth, a sales rep's leave-behind, or a national television ad ⟦c3⟧.
Large pharmaceutical companies running booths across multiple brands, indications, and stakeholder audiences face the sharpest version of this problem, because a single physical footprint has to resolve into one compliant, coherent narrative rather than several conflicting ones stitched together under one roof. Calling a space "medical" buys no exemption from oversight. It changes what kind of content is allowed and raises the evidentiary bar that content has to clear before it goes on a panel. Copy, imagery, product renderings, giveaways, and hospitality are all governed by industry codes and national medicines law no matter which side of that line the booth falls on.
What U.S. FDA promotional standards require of booth content
The Federal Food, Drug, and Cosmetic Act is a strict liability criminal statute ⟦c6⟧. Intent is beside the point ⟦c6⟧. A promotional claim that turns out to be false, misleading, or unbalanced against the risks can trigger an enforcement letter, real reputational damage, and in serious cases, criminal misbranding charges ⟦c6⟧. Different office, same underlying exposure.
A handful of requirements apply directly to what shows up on a booth panel. Claims have to stay consistent with the product's cleared or approved indication. Comparative claims need to be backed by data that the referenced study can actually support, not merely cited as though citation alone settles the matter. Investigational products cannot be shown as safe or effective in a commercial exhibit setting, and presenting an unapproved use inside that same commercial context is enough on its own to draw enforcement action.
The device side carries its own additional layer. OPEQ treats failure to apply Unique Device Identifiers and failure to submit the required GUDID data as violations in their own right, so any booth material referencing a device needs a check against those requirements specifically ⟦c9⟧. Digital health adds a newer wrinkle: AI-based device algorithms promoted without the proper regulatory authorization are becoming an active enforcement target, which matters directly for any booth featuring an AI-assisted diagnostic tool or software demo ⟦c10⟧. A boundary that booth teams sometimes blur without meaning to produces this pattern: the exhibit booth is a promotional space, full stop, while scientific exchange with health care professionals is a separate category governed by its own rules ⟦c8⟧.
How recent enforcement makes booth panel compliance concrete
None of this is theoretical. FDA issued more than 200 enforcement letters challenging advertising and promotion across drugs, biologics, and devices in 2025, and OPEQ alone accounted for 32 of those letters targeting device marketing violations ⟦c11⟧. Of the 74 letters sent to pharmaceutical and biologic manufacturers that year, exhibit booth panels were named specifically alongside social media, websites, newsletters, and sales aids as targeted material, and 16 of those letters challenged promotion aimed directly at health care professionals ⟦c12⟧.
One case makes the risk tangible. An exhibit panel carrying a table titled "REAL-WORLD COMPARISON OF ADHERENCE to Hemady® and generic dexamethasone among patients with MM" drew an OPDP enforcement letter in 2025 ⟦c13⟧. The company had cited "data on file" to support the comparison, but the underlying study's design and methodology did not actually support the adherence conclusions the panel presented. The lesson generalizes well beyond this one product: citing a source is not the same as being supported by it, and OPDP checks whether the study can bear the weight of the claim, not just whether a footnote exists ⟦c7⟧.
A more recent action pushes the point further. On August 21, 2026, OPDP issued an Untitled Letter to Alar Pharmaceuticals over promotional materials, including an exhibit booth display and brochure, for ALA-3000, an investigational ketamine pamoate injection ⟦c14⟧. FDA objected to the materials presenting ALA-3000 as safe or effective for treatment-resistant depression despite its investigational status, and to language implying it held advantages over already-approved therapies ⟦c15⟧. Framing something scientifically does not exempt it from the rule that investigational products cannot be promoted as though their safety and efficacy were settled.
Enforcement posture is also shifting in a way booth teams cannot ignore. In September 2025, FDA began using AI-powered surveillance tools to monitor drug advertising, issuing more than 100 warning letters in a stretch of time that followed a period of near-zero enforcement activity ⟦c16⟧. That newest batch of letters targeted HCP-directed materials exclusively, exhibit panels included ⟦c17⟧. Put together, the pattern is unambiguous: FDA is actively watching conference materials, comparative claims are judged on methodological soundness rather than the mere existence of a citation, and investigational products need a clean, visible separation from anything promotional ⟦c18⟧.
Off-label scientific exchange is permitted only outside the booth
FDA's finalized guidance on scientific information on unapproved uses, known as SIUU, took effect January 6, 2025, and it opens a narrow safe harbor for certain firm-initiated scientific communications with health care professionals ⟦c19⟧. The conditions attached to that safe harbor are specific: the communication has to be non-promotional, factual, and neutral in tone, and it has to be grounded in published, peer-reviewed literature or another authoritative clinical reference. Firms are still working out how implementation plays out in practice, which argues for caution rather than aggressive interpretation.
None of that changes what an exhibit booth is by default: a promotional space. Presenting an unapproved use there can draw enforcement regardless of how carefully scientific the framing sounds, because the setting itself carries the presumption of promotion. In a formally designated, physically separated space, a medical affairs zone, a one-on-one conversation with a medical science liaison, somewhere clearly distinct from a booth panel visible to every attendee walking the aisle ⟦c20⟧. That separation is exactly why the medical-affairs-versus-commercial distinction covered earlier is not a branding choice. It is the mechanism that keeps legitimate scientific exchange from being read as promotion of an unapproved use.
PhRMA Code requirements for giveaways, hospitality, and CME funding at U.S. booths
Federal law sets the floor. AdvaMed runs a parallel Code of Ethics for medical device companies built on the same underlying logic ⟦c21⟧. Any booth team working across both pharma and device products has to satisfy both codes at once, not pick whichever is more convenient for a given item ⟦c22⟧.
Giveaways get judged on a simple standard: modest value and a genuine educational or clinical purpose. That standard disqualifies the usual trade-show inventory immediately, plastic sunglasses, stress balls, anything resembling a high-end retail item. It goes further than dollar value, too. Golf balls and sports bags fail the test even when they cost almost nothing and even when they carry a company or product name, because they don't serve the clinician's practice or benefit patients in any direct way. The ASBrS 2026 Exhibitor Guidelines make this enforcement explicit at the congress level, citing PhRMA and AdvaMed by name in the section governing booth activities and giveaways, which shows that congress organizers themselves treat these codes as a condition of exhibiting, not a suggestion ⟦c27⟧.
CME funding carries its own separation requirement, and it's one of the easiest rules to violate without realizing it. Once a company funds continuing medical education, responsibility for the content, faculty selection, teaching methods, materials, and venue belongs entirely to the CME organizers ⟦c23⟧. The funding company should not offer input on content or faculty even when the organizer asks for it informally, because the prohibition covers those casual requests just as much as formal ones ⟦c24⟧. Enforcement bodies treat any indirect influence over funded CME as a serious compliance risk ⟦c25⟧. Speaker programs and satellite symposia held around a congress carry their own restriction: as of January 1, 2022, companies cannot pay for or provide alcohol at these events ⟦c26⟧, and high-end restaurants and comparably lavish venues are off the table as locations, no matter how convenient they are for a large evening event tied to the congress schedule. The PhRMA Code on Interactions with Health Care Professionals, a voluntary but widely adopted standard, was last revised effective January 1, 2022, and establishes the professional ethics baseline for pharma-HCP interactions in the U.S. ⟦c21⟧
Sunshine Act reporting of booth interactions
Everything described above eventually gets recorded. The Physician Payments Sunshine Act requires manufacturers of drugs, devices, biologicals, and medical supplies to report annually to CMS on payments or transfers of value made to physicians, teaching hospitals, and other covered recipients, a list that includes physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives ⟦c28⟧. CMS makes that data public every year by June 30 ⟦c28⟧. The scale of what gets captured is not small: Open Payments Program Year 2025 data runs to 17.07 million published records totaling $14.67 billion in payments and transfers of value ⟦c29⟧. Nearly every meaningful HCP interaction across the industry ends up documented somewhere in that dataset ⟦c29⟧.
The de minimis thresholds for 2025 get misread as a shield more often than they should, so they need to be known exactly ⟦c2⟧. Individual payments under $13.46 don't require reporting on their own ⟦c31⟧. But if total payments to one provider in a calendar year exceed $134.54, every single payment to that provider gets reported, including the ones that individually sat under the small-dollar threshold ⟦c32⟧. In effect, the threshold protects almost nothing once a clinician has more than one meaningful interaction with a company across a year, and a booth conversation that includes a meal, a branded item of real value, or a speaker fee for an adjacent symposium will likely push a provider over that line by itself.
Failing to report knowingly is not a paperwork slap on the wrist. HHS OIG can levy civil monetary penalties running from $10,000 to $100,000 per violation, capped at $1 million annually ⟦c33⟧. And the reporting net may widen further: the Open Payments Expansion Act, reintroduced September 4, 2025 by Senators Grassley and Hassan, would extend reporting obligations to financial relationships with tax-exempt patient advocacy organizations ⟦c34⟧, which matters directly to companies that fund patient group presence at congresses. Given all this, booth interactions need to be logged as they happen, not reconstructed weeks later from receipts and memory. Data capture belongs in the original booth plan, not bolted on afterward.
The European framework's changes to booth rules at international congresses
A booth built for a U.S. congress cannot be assumed to work unchanged at a European one, and the gap starts at the legal foundation ⟦c4⟧. EU Directive 2001/83/EC, Title VIII, together with the EFPIA Code, prohibits advertising prescription-only medicines to the general public under Article 88 ⟦c35⟧. That single rule reorganizes the entire physical layout of a European exhibit hall ⟦c4⟧. Public-facing surfaces of a pharmaceutical stand can carry disease-awareness content, corporate branding, or general scientific material, but never product promotion. Anything promotional has to sit behind a boundary that verifies HCP credentials before a visitor gets access ⟦c5⟧.
Some congresses handle that boundary by running two entirely separate exhibition areas, one restricted to health care professionals where promotional material is allowed, one open to the public where no direct or indirect promotion is permitted; others manage the same separation through differently coded lanyards or badges that keep non-HCPs out of promotional zones ⟦c36⟧. Patient organizations complicate this further, since they attend congresses regularly and the zoning has to accommodate their presence without letting them into promotional space meant only for clinicians.
The EFPIA Code prohibits gifts for the personal benefit of HCPs, hospital staff, or patient organization representatives, including sporting or entertainment tickets and social courtesy gifts, whether given directly or indirectly ⟦c37⟧.
National and European rules do not always align cleanly, either ⟦c4⟧. National hospitality allowances sometimes sit below the EFPIA baseline, and rules governing pharmaceutical meetings can differ from those governing device meetings even at the same event ⟦c39⟧. Where national and European codes conflict, and rules for pharmaceutical meetings differ from those for medical devices, with national HCP hospitality allowances sometimes lower than the EFPIA baseline, a documented compromise between the applicable rules is sometimes the only workable path forward ⟦c39⟧. None of it can be assumed to carry over from a U.S. booth design ⟦c4⟧. Content, physical zoning, data handling, and hospitality all need a fresh, market-specific review before the same booth appears on European soil ⟦c40⟧.
Translating the compliance framework into booth planning and operational decisions
All of this has to turn into a real pre-congress process. Regulatory review of every booth element, panels, brochures, digital displays, giveaway items, needs to happen against FDA promotional standards, PhRMA and AdvaMed code requirements, and, for European venues, EFPIA and national rules, and that review belongs before the design gets finalized, not after production is already paid for ⟦c41⟧.
Content decisions follow directly from the enforcement record already discussed. Every claim on a panel needs a study behind it that actually supports the conclusion. Investigational products need clean, visible separation from anything promotional. Off-label scientific exchange needs its own physical and procedural space, distinct from commercial booth activity. Comparative claims deserve the most scrutiny of all, since the Hemady example showed how a technically-cited claim can still fail once the underlying methodology gets examined ⟦c13⟧.
Physical design decisions carry the same weight as content decisions, and in European settings, arguably more ⟦c4⟧. Zoning is not decoration. HCP-only areas, public-facing areas, and scientific exchange spaces need to be mapped at the design stage, each with its own content plan attached ⟦c42⟧. Credential verification at those zone boundaries is a regulatory requirement in certain jurisdictions ⟦c43⟧. Giveaway selection needs the same discipline: confirm educational or clinical purpose and modest value before anything gets ordered, and keep the reasoning documented, because that documentation is what turns a defensible choice into a provable one if anyone asks later.
